Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASLAN 004

Drug Profile

ASLAN 004

Alternative Names: ASLAN-004; CSL334; IL-13R; IL-13R - Merck; IL-13Rα1 project; MK 6105

Latest Information Update: 18 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co; Zenyth Therapeutics
  • Developer ASLAN Pharmaceuticals; CSL; Merck & Co
  • Class Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-13 receptor alpha1 subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Atopic dermatitis
  • No development reported Asthma

Most Recent Events

  • 15 Oct 2018 Phase-I clinical trials in Atopic dermatitis (In healthy volunteers, and in atopic dermatitis patients) in Singapore (SC) (NCT03721263)
  • 15 Oct 2018 Phase-I clinical trials in Atopic dermatitis (In healthy volunteers, and in atopic dermatitis patients) in Singapore (IV) (NCT03721263)
  • 03 Jul 2018 ASLAN Pharmaceuticals files an IND application with the Singapore Health Sciences Authority (HSA) for Atopic dermatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top